DIALA EZZEDDINE, Ph.D.

Diala Ezzeddine was previously the CEO of Xios Therapeutics, a biotechnology company developing novel degrader therapeutics capable of preventing tumors from evading the immune system. She is passionate about Immuno-Oncology drug development, founding and building innovative startups, and helping shape the future of human health. Prior to Xios, Ezzeddine was CBO at X-Chem, a DNA encoded library platform company, the Head of Business Development at Archemix Corp, and a Senior Business Advisor at X-Body.